Newswire (Published: Monday, May 1, 2017, Received: Thursday, April 27, 2017, 10:16:15 AM CDT)

Word Count: 579

New Data from Georgetown University Illuminate Findings in Prostate Cancer (Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting from Washington, District of Columbia, by NewsRx journalists, research stated, "Randomized trials have shown that intermittent androgen deprivation therapy for patients with advanced prostate cancer may improve sexual and physical functioning compared to continuous androgen deprivation therapy without compromising survival. To our knowledge it is unknown whether intermittent androgen deprivation therapy alters the risk of serious toxicities associated with continuous androgen deprivation therapy."

The news correspondents obtained a quote from the research from Georgetown University, "We performed a population based cohort study of 9,772 men 66 years old or older who were diagnosed with advanced prostate cancer from 2002 to 2011 and treated with androgen deprivation therapy. Intermittent androgen deprivation therapy was defined as a single 90-day interval between 2 androgen deprivation therapy sessions during which patients visited their physicians or underwent prostate specific antigen testing. Outcomes included acute myocardial infarction, stroke, heart failure, type 2 diabetes and fracture. We used Cox proportional hazard models to estimate the HRs of the comparative risk of serious toxicities between intermittent and continuous androgen deprivation therapy. A total of 2,113 (22%), 769 (9%) and 899 men (9%) had a new cardiovascular event, diabetes or fracture, respectively, within 5 years of starting androgen deprivation therapy. Compared to the continuous androgen deprivation therapy group, the intermittent therapy group was at lower risk for serious cardiovascular events (HR 0.64, 95% CI 0.53-0.77), particularly in reducing the risk of heart failure (HR 0.62, 95% CI 0.49-0.78) and fracture (HR 0.52, 95% CI 0.38-0.70, each p< 0.0001). Intermittent androgen deprivation therapy was associated with a lower risk of heart failure and fracture compared to continuous androgen deprivation therapy."

According to the news reporters, the research concluded: "This raises toxicity concerns for continuous relative to intermittent therapy and suggests that intermittent androgen deprivation therapy may represent a safer therapeutic choice in elderly men with advanced prostate cancer."

For more information on this research see: Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study. Journal of Urology, 2017;197(5):1251-1257. Journal of Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier -; Journal of Urology -

Our news journalists report that additional information may be obtained by contacting H.T. Tsai, Georgetown University, Medical Center, Canc Prevent & Control Program, Lombardi Comprehens Canc CenterDept Oncol, Washington, DC 20007, United States. Additional authors for this research include R.M. Pfeiffer, G.K. Philips, A. Barac, A.Z. Fu, D.F. Penson, Y.J. Zhou and A.L. Potosky (see also Oncology - Prostate Cancer).

Keywords for this news article include: Washington, District of Columbia, United States, North and Central America, Nutritional and Metabolic Diseases and Conditions, Non-Insulin Dependent Diabetes Mellitus, Cardiovascular Diseases and Conditions, Heart Disorders and Diseases, Drugs and Therapies, Risk and Prevention, Prostatic Neoplasms, Type 2 Diabetes, Prostate Cancer, Heart Failure, Heart Disease, Cardiology, Androgens, Oncology, Therapy, Georgetown University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


The Georgetown University


Central America
North America
United States
District of Columbia
New York
New York City


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Endocrine Disorders
            Men's Health Issues
                  Prostate Cancer
            Metabolic Disorders
            Urological Diseases
      Medical Specialties and Practices
      Medical and Pharmaceutical Regulation
            Drug and Device Approval Process
      Treatments and Therapies
            Medicinal Drugs